WHO ICTRP trial
A single center, open-label, dose escalation study of the safety and…
EUCTR2010-022084-36-DK · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2010-022084-36-DK |
|---|---|
| Public title | A single center, open-label, dose escalation study of the safety and pharmacokinetics of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-mannosidosis. |
| Scientific title | A single center, open-label, dose escalation study of the safety and pharmacokinetics of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-mannosidosis. |
| Primary sponsor | Zymenex A/S |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Denmark |
| Conditions | Treatment of alpha-Mannosidosis |
| Interventions | Product Name: Lamazym Product Code: rhLAMAN Pharmaceutical Form: Solution for infusion INN or Proposed INN: recombinant human alpha-mannosidase Current Sponsor code: rhLAMAN Concentration unit: mg/ml milligram(s)/millilitre Concentration… |
| Registration date | Aug 20, 2010 |
| Target size | 10 |
| Secondary IDs | rhLAMAN-02 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: